Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
“The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
The vascular endothelium is a highly specialized, metabolically active organ that plays a pivotal role in cardiovascular homeostasis. It regulates vascular tone, platelet activity, leukocyte adhesion, oxidative balance, and thrombosis primarily through the synthesis of vasoactive mediators, notably nitric oxide (NO). In healthy individuals, endothelial cells maintain high NO bioavailability, which promotes vasodilation, inhibits smooth muscle proliferation, suppresses inflammation, and prevents platelet aggregation.
Epidemiological and mechanistic studies consistently demonstrate that endothelial dysfunction precedes overt atherosclerosis by decades. Flow-mediated dilation (FMD), a validated marker of endothelial function, declines progressively with age—approximately 0.5–1.0% per decade in low-risk populations—and is markedly impaired in individuals with traditional cardiovascular risk factors. Large cohort studies show that a 1% reduction in FMD is associated with an 8–13% increase in future cardiovascular events.
Reduced NO bioavailability is a hallmark of endothelial dysfunction and is strongly linked to atherosclerotic progression. Experimental and clinical data indicate that NO production may decline by 40–60% in middle-aged adults with metabolic syndrome or diabetes, accelerating lipid oxidation, vascular inflammation, and plaque formation. In advanced stages, severe NO depletion (<20% of physiological levels) is associated with arterial stiffening, plaque instability, and a significantly increased risk of thrombotic events.
Clinically, endothelial dysfunction independently predicts myocardial infarction, stroke, and cardiovascular mortality, even after adjustment for conventional risk factors. Meta-analyses involving over 20,000 patients demonstrate that impaired endothelial function confers a 1.7–2.3-fold higher risk of major adverse cardiovascular events. These findings underscore that endothelial health is not merely a marker but a central driver of cardiovascular disease complexity, progression, and clinical outcomes—making it a critical therapeutic target in modern preventive cardiology.”

More posts featuring Ney Carter Borges.
-
Feb 1, 2026, 12:05Causes of Anemia – A Quick Overview From Mahnoor Shah
-
Feb 1, 2026, 11:58Michael Makris: Moving Letter from Minnesota Physicians
-
Feb 1, 2026, 11:50Wolfgang Miesbach on The 1st Case of Secondary Malignancy Triggered by Integrated AAV
-
Feb 1, 2026, 11:48Irma Bagdoniene: Statin Intolerance – Challenges and Solutions
-
Feb 1, 2026, 11:42Khokon Miah Akanda: 2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke
-
Feb 1, 2026, 11:35Benjamin Terrier Shares A PhD Opportunity In Immunology
-
Feb 1, 2026, 11:32Qizhen Shi։ A Padua Moment for Factor VIII Gene Therapy
-
Feb 1, 2026, 11:25Abdul Mannan: Breaking Down the New BSH Hepatitis Guideline for Haemophilia Nurses
-
Feb 1, 2026, 11:24Nathan Wong on Economic Benefits of Inclisiran for LDL-C Control